Here Are My Top 4 Stocks to Buy in October

The article highlights four stocks it views as promising for Q4, citing Viking Therapeutics' differentiated VK2735 dosing potential, Google Cloud's 82% year-over-year growth and Q2 market-share gains, SoFi's 40% adjusted-revenue growth to $1.2 billion and raised full-year revenue guidance of $4.75 billion–$4.85 billion, and MercadoLibre's 50% revenue growth to nearly $10.2 billion. MercadoLibre shares were down 25% over the past year, while analysts' consensus 12-month price target of $2,295.31 implies 36% upside. The outlook is favorable but relies on upcoming reports and clinical progress; the article gives no scheduled Q4 trial update for Viking's monthly-dose approach, which remains in Phase 1.

Analysis

The article is a bullish watchlist, not evidence that all four setups have asymmetric upside. The key distinction is catalyst quality: GOOG and MELI have operating metrics that can be tested in upcoming results; SOFI needs proof that growth survives the Galileo transition and credit-cycle pressure; VKTX remains a clinical- and valuation-sensitive option on future efficacy, not a near-term earnings story.

For GOOG, the market may be underweighting distribution advantages, but cloud growth alone does not establish durable share gains or attractive returns on AI investment. Track cloud backlog, operating margin, capex, and Search monetization. A margin deterioration alongside elevated investment would invalidate the re-rating case. Relative value versus MSFT is more defensible than assuming broad AI sentiment turns positive.

For MELI, deeper engagement can increase lifetime value, but free shipping is only accretive if repeat purchasing and payments economics ultimately offset fulfillment costs. Brazil competition, currency volatility, and credit losses are material counterweights. For SOFI, reported growth matters less than whether Galileo replacement activity and lending quality offset the departing client; the accounting allegations also warrant independent verification rather than dismissal as sentiment.

VKTX’s differentiated dosing concept is a long-dated possibility, not yet a basis to capitalize commercial success. Trial efficacy, tolerability, dosing durability, and financing/dilution exposure matter more than broad market-size estimates. The contrarian risk across the list: optimistic narratives may already price in execution, while the article supplies no valuation or consensus data to establish that they do not.

Key Decisions for Investors

• Prefer a conditional GOOG-versus-MSFT relative-value position over an outright AI-sector bet: initiate only if the next report confirms cloud growth with stable or improving profitability and capex discipline. Reassess on margin deterioration or weaker Search monetization.
• Treat MELI as a staged long/watchlist candidate, not a margin-blind growth purchase. Add only if subsequent results show shipping investment stabilizing relative to gross profit while engagement translates into repeat spend and payments growth; reduce on worsening Brazil unit economics, FX stress, or credit quality.
• Keep SOFI event-driven and sized around uncertainty. Before adding, verify Galileo customer replacement/retention, technology-platform revenue trajectory, loan delinquency and charge-off trends, and the status of the accounting allegations. Deterioration in credit metrics or guidance would falsify the recovery thesis.
• Keep VKTX as a speculative clinical watch rather than a core position. Confirm the actual timing and scope of trial disclosures, then assess efficacy and safety against established GLP-1 alternatives; do not assign commercial value to monthly maintenance dosing before meaningful clinical evidence.